The New Freezing of Gait Questionnaire: Unsuitable as an Outcome in Clinical Trials?

Femke HulzingaAlice NieuwboerBauke W DijkstraMartina ManciniCarolien StrouwenBastiaan R BloemPieter Ginis

Published in: Movement disorders clinical practice (2020)

We conclude that the NFOG-Q is insufficiently reliable or responsive to detect small effect sizes, as changes need to go beyond 35% to surpass measurement error. Therefore, we warrant caution in using the NFOG-Q as a primary outcome in clinical trials. These results emphasize the need for robust and objective freezing of gait outcome measures.

Keyphrases

clinical trial
phase ii
cerebral palsy
open label
cross sectional
double blind
cancer therapy
phase iii
study protocol
drug delivery